S1104
Clinical – Upper GI
ESTRO 2026
References: 1.
months). Local control rates for Cohort 1 at 6 and 12 months were 86.7% (n=13/15) and 60% (n=6/10) respectively. Distant progression-free survival at 6 and 12 months was 66.7% (n=12/18) and 26.7% (n=4/15) respectively. Overall survival at 6 and 12 months was 88% (n=22) and 84% (n=21) respectively. Cohort 2 (n=19) had a median age of 68 years (range 47-83 years) and median follow-up of 4.6 months (range 0.6- 29 months). Overall survival at 6 and 12 months was 78.9% (n=15/19) and 47.7% (n=9/19) respectively. Cohort 3 (n=10) had a median age of 68.5 years (range 36-75 years) and median follow-up of 5.6 months (3.3-15.5 months). The most common primaries were neuroendocrine tumours (n=2) and renal cell carcinomas (n=2). Overall survival at 6 and 12 months was 100% and 90% respectively. Recorded toxicities showed 7 acute G3 toxicities and 8 late >G3 toxicities, with the most common being biliary obstruction (n=7) and partial small bowel obstruction (n=2). Conclusion: This first Australian study on MRgRT for LAPC highlights the promising potential for local control and relatively low >G3 toxicity rates. References: 1 Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study Chuong, Michael D. et al. Radiotherapy and Oncology, Volume 191, 110064 2 Heerkens Marco; Erickson, B. R. O. I. M. van den B. C. A. T. M. I. Q. V. F. P. ; M. G. J. H. D. ; van V. MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. Br J Radiol 91, 20170563–NA (2018). Keywords: MRgRT, pancreas, SBRT CBCT-based Online Adaptive RadioTherapy for Esophageal Cancer (ARTEC): Preliminary Results of a Prospective Single-Center Study Nicolas Bachmann 1 , Moritz Hürlimann 1 , Daniel Schmidhalter 2 , Jenny Bertholet 2 , Martin D. Berger 3 , Yves Borbély 4 , Daniel M. Aebersold 1 , Peter Manser 2 , Hossein Hemmatazad 1 1 Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 2 Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 3 Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 4 Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland Digital Poster Highlight 3726
Shitara K, Fleitas T, Kawakami H et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open 2024; 9: 102226. doi:10.1016/j.esmoop.2023.1022262. Japanese Gastric Cancer A. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 2023; 26: 1-25. doi:10.1007/s10120-022-01331-83. Yim K, Jang WM, Lee SH. Modified Tumor Budding as a Better Predictor of Lymph Node Metastasis in Early Gastric Cancer: Possible Real-World Applications. Cancers (Basel) 2021; 13. doi:10.3390/cancers13143405 Keywords: intramucosal gastric cancer, endoscopic resection Digital Poster 3657 MR-Guided Stereotactic Radiotherapy for pancreatic tumours: A Promising Approach for Local Control with Low Toxicity Yew K Sin 1 , Lyndsey Edwards 1 , Farshad Kasraei 2 , Hilary Byrne 2 , Adarsh Das 3 , Eugene Leong 1 , Kasri Rahim 1 , Jeremy De Leon 2 , Hendrick Tan 1 1 Radiation Oncology, GenesisCare, Perth, Australia. 2 Radiation Oncology, GenesisCare, Sydney, Australia. 3 Parkville Integrated Palliative Care Service, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia
Purpose/Objective: Locally-advanced pancreatic cancer (LAPC) has a poor
prognosis and radiation dose escalation has demonstrated promising local control rates,
potentially translating to better overall survival. The emergence of MR guided radiotherapy (MRgRT)1 has permitted real-time adaptive, dynamic guidance with superior soft tissue delineation to enable delivery of ablative doses to the pancreas safely2. This study evaluated the efficacy and tolerability of MRgRT in primary LAPC. Material/Methods: Data was collected from a dual-institution registry for patients receiving SBRT (45-50Gy in 5 fractions) to the pancreas. Included were patients with unresectable LAPC receiving upfront chemotherapy (Cohort 1), patients with metastatic pancreatic cancer receiving upfront chemotherapy (Cohort 2), and patients with secondary pancreatic cancer (Cohort 3). The endpoints studied were acute and late >G3 toxicities (CTCAE v5.0), local control, distant progression-free survival and overall survival. Results: 54 patients were enrolled. Cohort 1 (n=25) had a median age of 73 years (range 49-91 years) and median follow-up of 10 months (range 3.3-36.9
Made with FlippingBook - Share PDF online